CBL404
Anti-p53 Antibody, aa 211-220, clone240
clone PAb240, Chemicon®, from mouse
Synonym(s):
Anti-p53 antibody
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
PAb240, monoclonal
species reactivity
hamster, monkey, mouse, chicken, human, rat, bovine
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1
suitability
not suitable for immunohistochemistry (Paraffin)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
Gene Information
human ... TP53(7157)
General description
p53 was discovered in 1979 as a cellular protein associating with the transforming protein of SV40 tumor virus. Since then, many different biochemical functions have been attributed to the 53 kD phosphoprotein. Experimental evidence has suggested that p53 acts as a negative regulator of cell growth in normal cells (Finlay, 1989). Thus, the inactivation or mutation of p53 may be an essential step in the development of malignancy (Lane and Benchmol, 1990). Wild-type p53 levels in normal cells and tissues were found to be very low. Mutant p53 polypeptide, however, is often found to be present at high concentrations in mammalian tumors and tumor cell lines. For example, in an immuno-histochemistry study 40% of human breast cancer showed elevated levels of mutant p53 in the cell nucleus. Mutations of the p53 protein have some characteristic features:
a) Most of them are missense point mutations giving rise to an altered protein function.
b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.
a) Most of them are missense point mutations giving rise to an altered protein function.
b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.
Specificity
PAb 240 recognizes an epitope of p53 tumor suppressor protein between amino acids 211 and 220 (Gannon, 1990; Legros, 1994) in human, mouse, rat, hamster, monkey, cow and chicken. Assaying native samples (immunoprecipitation, ELISA) the PAb 240 detects only the mutant forms of p53 (Gannon, 1990; Said, 1994). In methods using denatured samples [Western blot analysis (Gannon, 1990) and immunohistochemistry of frozen tissue sections (Said, 1994; Bartek, 1991; Walker, 1991)], the PAb 240 recognizes both mutant and denatured wild-type p53.
Immunogen
Epitope: aa 211-220
Murine p53-beta galactosidase fusion protein expressed in E. coli.
Application
Detect p53 with Anti-p53 Antibody, aa 211-220, clone240 (Mouse Monoclonal Antibody), that has been shown to work in IP, WB & IHC.
Detection of p53 oncogene protein
Detection of mutant p53
Prevalence of detection using CBL 404
-50% colon carcinoma sections positive (30 samples)
-70% lung carcinoma sections positive (50 samples)
-30% carcinoma breast samples positive (50 samples)
Normal and pre-malignant tissues negative
Reacts on methacarn fixed tissue
Optimal working dilutions must be determined by the end user.
Detection of mutant p53
Prevalence of detection using CBL 404
-50% colon carcinoma sections positive (30 samples)
-70% lung carcinoma sections positive (50 samples)
-30% carcinoma breast samples positive (50 samples)
Normal and pre-malignant tissues negative
Reacts on methacarn fixed tissue
Optimal working dilutions must be determined by the end user.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Linkage
Replaces: 04-1083
Physical form
Format: Purified
Purified mouse monoclonal in buffer containing 0.1M Tris-glycine (pH 7.4), 0.15M NaCl, with 0.05% sodium azide. We recommend that each laboratory determine an optimum working titre for use in its particular application.
Storage and Stability
For use within 1 month of purchase store at +4°C, for long term storage aliquot antibody into small volumes and store at -20°C.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Iggo, R, et al.
Lancet, 335, 675-679 (1990)
Rajan Gogna et al.
The Journal of biological chemistry, 287(4), 2907-2914 (2011-12-08)
Mutant (Mt) p53 abrogates tumor suppression functions of wild-type (WT) p53 through mutant-specific, gain-of-function effects, and patients bearing Mt p53 are chemoresistant. The dominant negative effect of p53 mutants results from their aggregation propensity which causes co-aggregation of WT p53.
Siddharth Singh et al.
The Journal of biological chemistry, 294(38), 14081-14095 (2019-08-02)
TP53 is the most frequently mutated tumor suppressor gene in many cancers, yet biochemical characterization of several of its reported mutations with probable biological significance have not been accomplished enough. Specifically, missense mutations in TP53 can contribute to tumorigenesis through
The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain
Srinivasan, A, et al
Molecular and cellular biology, 17, 4761-4773 (1997)
Eric Chekwube Aniogo et al.
Molecules (Basel, Switzerland), 26(23) (2021-12-11)
Multidrug resistance (MDR) has posed a significant threat to cancer treatment and has led to the emergence of a new therapeutic regime of photodynamic therapy (PDT) to curb the menace. The PDT modality employs a photosensitiser (PS), excited at a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service